## Docket No. 13720-105065US1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	(s): Jacob Waugh et al.			
Serial No	.: 09/910,432	Group Art Unit:	1635	
Filed:	July 20, 2001	Examiner: Confirmation No:	Richard A. Schnizer 2657	
For:	Multi-Component Biolo	Multi-Component Biological Transport Systems		
P.O. Box	a, VA 22313-1450			
	SUPPLEMENTAL INFO	RMATION DISCLOSURE S	<u>TATEMENT</u>	
Sir:				
	This Information Disclos	sure Statement is filed in accord	lance with 37 C.F.R.	
§§1.56, 1.	97 and 1.98. The items listed	on Form PTO-SB08, a copy of	f which is enclosed, are	
made of r	ecord to assist the Patent and	Trademark Office in its examin	ation of this application.	
The Exan	niner is respectfully requested	to fully consider the items and	to independently ascertain	
heir teach	ning.			
1. 🗌	not in the English language, a	ms listed on the enclosed copy on English language translation of the relevance of that item	of that item or a portion	
2.	not in the English language, a	ns listed on the enclosed copy of a concise explanation of the reletion of the above-identified apple	evance of that item is	
3.	enclosed with this Informatio	on the enclosed copy of Form Pon Disclosure Statement was pre Frademark Office in application	eviously cited by or	
	·			
1. 🗌	No fee is due under 37 C.F.R since it is being filed in comp	. §1.17(p) for this Information liance with:	Disclosure Statement	
	37 C.F.R. §1.97(b)(1) application other than	, within three months of the fili a CPA; or	ng date of a national	
		, within three months of the datorth in §1.491 in an internations		

		37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or	
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.	
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
it is being filed in compliance with 3 paragraph 4 above but before the ma		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):	
		A check in the amount of \$180.00 is enclosed in payment of the fee.	
		Charge the fee to Deposit Account No. <u>50-3732</u> , Order No. <u>13720-105065</u> .	
7.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:	
		a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and	
		b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.	
8.		This Information Disclosure Statement is being filed in compliance with:	
		a. 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
		b. 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
		c. The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.	
9.		I hereby certify that each item of information contained in this Information Disclosur Statement was first cited in a communication from a foreign patent office in a	

	counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.	
10.	This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.	
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).	
	Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No	
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105065.	
Dated: J	Respectfully submitted, KING & SPALDING LLP  By:  Jøseph D. Eng, Jr.  Reg. No. 54,084	

## Correspondence Address:

King & Spalding LLP 1185 Avenue of the Americas New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile